AD is a progressive neurodegenerative disorder and a leading cause of dementia in an
aging population worldwide. The enormous challenge which AD possesses to global …

Some cannabinoids activate the different isoforms of PPARs (α, β and γ), as shown through
the use of reporter gene assays, binding studies, selective antagonists and knockout …

The psychoactive constituent in cannabis, Δ9-tetrahydrocannabinol (THC), was isolated in
the mid-1960s, but the cannabinoid receptors, CB1 and CB2, and the major endogenous …

There are at least two types of cannabinoid receptors (CB1 and CB2). Ligands activating
these G protein-coupled receptors (GPCRs) include the phytocannabinoid Δ9 …

Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors
including PPARα, PPARγ, and PPARβ/δ, acting as transcription factors to regulate the …

BACKGROUND: Cannabinoid agonists are potential therapeutic agents because of their
antinociceptive and anxiolytic-like effects, although an important caveat to their use is the …

Cannabis has long been known to produce cognitive and emotional effects. Research has
shown that cannabinoid drugs produce these effects by driving the brain's endogenous …

The existence of acylethanolamides (AEs) in the mammalian brain has been known for
decades. Among AEs, palmitoylethanolamide (PEA) is abundant in the central nervous …

Extensive evidence indicates that endocannabinoids modulate cognitive processes in
animal models and human subjects. However, the results of endocannabinoid system …

Cannabinoids (CBs) are used to treat chronic pain, chemotherapy-induced nausea and
vomiting, and multiple sclerosis spasticity. Recently, the medicinal use of CBs has attracted …